Anidulafungin(Vicuron Pharmaceuticals) is a new echinocandin antifungal with potent activity against Aspergillus and Candida spp.Anidulafungin is a noncompetitive inhibitor of(1,3)-beta-D-glucan synthase within fungal cells.Its features include a larger distribution volume and potentially broader and more potent antifungal activities than other echinocandins.Anidulafungin is in Phase Ⅲ stage of clinical studies in USA.This paper introduces the mechanism,pharmacodynamics,pharmacokinetics and clinical therapeutics of anidulafungin.